XML 58 R29.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of Significant Accounting Policies Summary of Significant Accounting Principles (Tables)
 12 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
Debt Securities, Held-to-maturity
The following is a summary of the net carrying amount, unrealized gains, unrealized losses, and fair value of held-to-maturity securities by type and contractual maturity as of June 30, 2023 and 2022.

June 30, 2023
Amortized costUnrealized lossesFair value
Due within one year or less:
Commercial paper$15,982 $(10)$15,972 
Corporate debt securities16,298 (190)16,108 
U.S. government securities6,260 (69)6,191 
Total due within one year or less38,540 (269)38,271 
Due between one and two years:
Corporate debt securities1,498 (35)1,463 
U.S. government securities2,999 (66)2,933 
Total due between one and two years4,497 (101)4,396 
Total held-to-maturity securities$43,037 $(370)$42,667 

June 30, 2022
Amortized costUnrealized lossesFair value
Due within one year or less:
Corporate debt securities$49,952 $(546)$49,406 
Total held-to-maturity securities$49,952 $(546)$49,406 
Schedule of Other Nonoperating Income (Expense)
The following table summarizes the components of other income (expense), net:
 Year Ended June 30,
202320222021
Gains (losses) on derivatives not designated as hedging instruments (1)$3,311 $58,148 $(20,728)
Currency-related gains, net (2)16,350 244 1,005 
Other (losses) gains(1,163)3,071 370 
Total other income (expense), net$18,498 $61,463 $(19,353)
_____________________
(1) Includes realized and unrealized gains and losses on derivative currency forward and option contracts not designated as hedging instruments, as well as the ineffective portion of certain interest rate swap contracts that have been de-designated from hedge accounting. For contracts not designated as hedging instruments, we realized gains of $39,133 and $9,955, respectively, for the years ended June 30, 2023 and 2022, and losses of $6,854 for the year ended June 30, 2021. Refer to Note 4 for additional details relating to our derivative contracts.
(2) Currency-related gains, net primarily relates to significant non-functional currency intercompany financing relationships that we may change at times and are subject to currency exchange rate volatility. In addition, we have certain cross-currency swaps designated as cash flow hedges, which hedge the remeasurement of certain intercompany loans; refer to Note 4 for additional details relating to these cash flow hedges.
Schedule of Weighted Average Number of Shares
The following table sets forth the reconciliation of the weighted-average number of ordinary shares:
 Year Ended June 30,
 202320222021
Weighted average shares outstanding, basic and diluted26,252,860 26,094,842 25,996,572 
Weighted average anti-dilutive shares excluded from diluted net loss per share attributable to Cimpress plc (1)(2)2,834,351 762,086 494,329 
___________________
(1) In the periods in which a net loss is recognized, the impact of share options, RSUs, restricted share awards, and warrants are anti-dilutive. For the years ended June 30, 2023, 2022, and 2021, the weighted average dilutive shares for these securities, in the aggregate, would have been 83,275, 233,244, and 465,869, respectively, had we not recognized a net loss.
(2) On May 1, 2020, we entered into a financing arrangement with Apollo Global Management, Inc., which included 7-year warrants to purchase 1,055,377 of our ordinary shares with a strike price of $60 that have a potentially dilutive impact on our weighted average shares outstanding. For the years ended June 30, 2022 and 2021, the average market price was higher than the strike price for at least a portion of the year, as such the weighted average dilutive effect of the warrants that were included in the anti-dilutive share count due to the net loss in each period was 138,088, and 368,933 shares, respectively. For the year ended June 30, 2023, the average share price was below the strike price for the full fiscal year; therefore, the total outstanding warrants were considered anti-dilutive.